RESUMEN
A monoclonal antibody (17F11) was raised by immunization of a Balb/c mouse with leukemic blasts from a patient with acute non-lymphocytic leukemia (ANLL). This antibody recognizes most leukemic blasts of myeloid but not of lymphoid lineage and no peripheral blood cells. By screening NIH-3T3 fibroblasts transfected with the human proto-oncogene c-kit (NIH-3T3/hckit) it could be shown that 17F11 specifically recognizes the gene product P145c-kit. Immunofluorescence analysis on normal hemopoietic cells revealed that 17F11 weakly stains 1-3% of bone marrow mononuclear cells (BMMNC). By FACS sorting and colony assays it could be shown that granulocyte--macrophage progenitor cells could be enriched 10-20-fold, granulocyte progenitors 50-80-fold, and erythroid and multipotential progenitor cells 15-20-fold, in the 17F11 positive fraction. Double fluorescence analysis revealed that P145c-kit is co-expressed on 40-60% of the CD34 positive BMMNC. Finally, these data show that P145c-kit is expressed on blast cells from most patients with ANLL (26/30) and chronic myeloid leukemia in blast crisis (7/9), but is absent on blasts from patients with acute lymphoblastic leukemia expressing the T-, B-lineage, or common ALL phenotypes.
Asunto(s)
Antígenos de Neoplasias/genética , Antígenos de Superficie/genética , Células Madre Hematopoyéticas/inmunología , Leucemia Mieloide Aguda/genética , Proteínas Proto-Oncogénicas/genética , Proto-Oncogenes/genética , Animales , Anticuerpos Monoclonales/inmunología , Antígenos CD/fisiología , Antígenos CD34 , Antígenos de Neoplasias/inmunología , Antígenos de Superficie/inmunología , Médula Ósea/inmunología , Médula Ósea/fisiología , Células de la Médula Ósea , Células Cultivadas , Expresión Génica , Células Madre Hematopoyéticas/fisiología , Humanos , Leucemia Mieloide Aguda/inmunología , Leucemia Mieloide Aguda/patología , Ratones , Ratones Endogámicos BALB C , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas c-kit , Células Tumorales CultivadasRESUMEN
One of the major endpoints of cellular immunological tests remains the quantitative assessment of lymphocyte proliferation as estimated from incorporation of tritiated thymidine into dividing cells. These data are usually generated by beta scintillation counting as strings of counts per minute which require considerable data reduction and processing. A computer system for the collection, transfer, presentation, processing and storage of these data is outlined here. This is based on modules operating from a basic system of maximal simplicity and flexibility in which data are stored in ASCII files and where the particular data processing requirements of different investigators can be easily met. This is exemplified by using a number of examples from the authors' own experiments, also illustrating the point that proliferative responses of non-lymphoid cells can be processed in the same way. In addition, suggestions are made concerning the standardisation of data processing for the exchange of results between different laboratories collaborating in large scale investigations, for example, the International Histocompatibility Workshops.
Asunto(s)
Diagnóstico por Computador , Recuento de Leucocitos/instrumentación , Leucocitos Mononucleares , Activación de Linfocitos , Timidina , Humanos , Leucocitos Mononucleares/inmunología , Diseño de Software , Interfaz Usuario-ComputadorRESUMEN
The effects of exogenous cytokines on the generation of alloindifferent, MHC-unrestricted suppressive activity early on in mixed lymphocyte culture interactions have been investigated. Interleukin 4 strongly blocked the generation of suppression, whereas IL-1, IL-2, and IL-6 enhanced it to some extent. Tumor necrosis factor-alpha, interferons-alpha and -gamma, granulocyte/macrophage colony-stimulating factor, granulocyte CSF, IL-3 and IL-5, and a number of combinations of these factors were without effect in this system. Insofar as the alloindifferent suppression studied here also inhibited the development of allospecific, MHC restricted suppressive activity later in MLC, reduction by IL-4 of its development may have relevance for the use of this cytokine to facilitate the induction of specific suppressor cell-mediated transplantation tolerance in vivo.
Asunto(s)
Factores Biológicos/farmacología , Antígenos HLA/inmunología , Antígenos HLA-DR/inmunología , Prueba de Cultivo Mixto de Linfocitos , Linfocinas/farmacología , Linfocitos T Reguladores/inmunología , Factores Estimulantes de Colonias/farmacología , Citocinas , Factor Estimulante de Colonias de Granulocitos , Factor Estimulante de Colonias de Granulocitos y Macrófagos , Sustancias de Crecimiento/farmacología , Humanos , Técnicas In Vitro , Interferón Tipo I/farmacología , Interferón gamma/farmacología , Interleucina-4/farmacología , Complejo Mayor de Histocompatibilidad , Proteínas Recombinantes , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic lymphokine which may have important regulatory effects on immune responses. It is shown here that eight alloreactive CD4+ T cell clones (TCC) secreted significant amounts of TNF-alpha after stimulation with either specific alloantigen or 12-O-tetradecanoylphorbol 13-acetate together with the calcium ionophore ionomycin (up to 50 ng/ml/24 h/10(6) cells) whereas CD8+ TCC failed to do so (max. 2 ng/ml/24 h/10(6) cells). The CD8+ TCC also secreted markedly less granulocyte/macrophage colony-stimulating factor than the CD4+ cells. However, this was not indicative of a general decrease of lymphokine production by CD8+ cells because CD4+ and CD8+ TCC both secreted similar amounts of interferon-gamma. These results show that regulatory CD4+ lymphocytes can produce large amounts of TNF-alpha, whereas CD8+ effector cells cannot do so.
Asunto(s)
Factores Estimulantes de Colonias/metabolismo , Sustancias de Crecimiento/metabolismo , Interferón gamma/metabolismo , Linfocitos T Colaboradores-Inductores/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Células Clonales/clasificación , Células Clonales/inmunología , Células Clonales/metabolismo , Factor Estimulante de Colonias de Granulocitos y Macrófagos , Humanos , Activación de Linfocitos , Fenotipo , Linfocitos T Citotóxicos/inmunología , Linfocitos T Citotóxicos/metabolismo , Linfocitos T Colaboradores-Inductores/clasificación , Linfocitos T Colaboradores-Inductores/inmunologíaRESUMEN
The frequencies of HLA-DP alleles in 50 acute lymphocytic, 43 acute non-lymphocytic, 50 chronic myelogenous and 51 chronic lymphocytic leukaemia patients were compared with 254 controls using primed lymphocyte typing. In CLL and ANLL there were significantly decreased frequencies of DPw1. Decreased DPw1 and DPw3 was observed in ALL, but after correction for the number of comparisons made this was no longer significant. However, in ALL, even after correction, there were significantly increased frequencies of DPw2 and DPw5, whereas in ANLL and CLL the only significant increases were of DP-blank, and in CML there were no positive or negative associations at all. These results suggest an influence of DP alleles in disease susceptibility and resistance in three of the four major types of leukaemia.
Asunto(s)
Antígenos HLA-DP/genética , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Mieloide Aguda/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Alelos , Genes MHC Clase II , HumanosRESUMEN
Positive and negative signals for clonal expansion of preactivated human CD4+ alloreactive Th cells have been examined. Fifteen T cell clones tested 3 days after Ag-specific stimulation proliferated with IL-2 but only five of these responded to IL-4. The remaining 10 also failed to respond to IL-4 in the presence of IL-1 and/or autologous B-LCL. The response of the latter five to IL-4 was independent of IL-2 as shown by the inability of IL-2R mAb to prevent proliferation. In contrast, transferrin R mAb blocked responses to both IL-2 and IL-4. IL-4 responder but not nonresponder clones demonstrated IL-4-enhanced responses to suboptimal concentrations of IL-2 (1 U/ml), but none of the clones showed enhanced responses with 1 U/ml IL-2 plus IL-1, IL-3, IL-5, or granulocyte-macrophage-CSF. IFN-gamma did not enhance or inhibit responses to either IL-2 or IL-4. TNF-alpha did not block proliferation supported by IL-4. In contrast, TNF-alpha did block proliferative responses to IL-2, but only by those clones which were incapable of responding to IL-4. Thus, proliferation of the IL-4-responder clones was not blocked by TNF-alpha when optimal or even supraoptimal concentrations of IL-2 were used as growth factor. Because all T cell clones themselves secreted TNF-alpha after specific stimulation, these results suggest a novel autocrine negative regulatory pathway, whereby IL-4-reactive helper cells would have a selective advantage over IL-4-nonreactive cells during the evolution of an immune response.
Asunto(s)
Inhibidores de Crecimiento/farmacología , Interleucinas/farmacología , Activación de Linfocitos , Linfocitos T Colaboradores-Inductores/inmunología , Factor de Necrosis Tumoral alfa/farmacología , Diferenciación Celular/efectos de los fármacos , Células Clonales/inmunología , Células Clonales/fisiología , Humanos , Inmunidad Innata/efectos de los fármacos , Inmunosupresores/farmacología , Interleucina-2/farmacología , Interleucina-4 , Activación de Linfocitos/efectos de los fármacos , Linfocitos T Colaboradores-Inductores/fisiologíaRESUMEN
Requirements for stimulating autocrine proliferation of human T cell clones expressing either alpha/beta or gamma/delta antigen receptors via the "alternative" CD2 pathway have been examined using a large set of monoclonal antibodies (mAb). In the presence of autologous accessory cells (AC, B-lymphoblastoid cell lines) 2 of 13 single CD2 mAb (CLB-T11.1/1 and 6F10.3) stimulated proliferation of gamma/delta but not alpha/beta cells. Interleukin (IL) 1 or IL 6 did not substitute for AC in stimulating gamma/delta clones. Addition of CD28 mAb YTH 913.12 with the CD2 mAb did not result in stimulation of any alpha/beta clones. In the absence of AC, none of the CD2 mAb singly could stimulate any T cell clones, but pairs of mAb directed to different epitopes of CD2 (CLB-T11.1/1 + CLB- T11.2/1 or 6F10.3 + 39C1.5) stimulated both alpha/beta and gamma/delta clones. In both cases, stimulation was reduced by the presence of CD3 mAb. These results confirm that the established AC-independent alternative pathway of T cell activation, which requires binding of two separate epitopes of CD2, operates in both gamma/delta and alpha/beta T cells, and further suggest that an additional pathway initiated by binding of a single CD2 epitope in the presence of AC is exclusively operational in gamma/delta cells.
Asunto(s)
Antígenos CD/fisiología , Antígenos de Diferenciación de Linfocitos T/fisiología , Receptores de Antígenos de Linfocitos T/fisiología , Receptores Inmunológicos/fisiología , Linfocitos T/inmunología , Anticuerpos Monoclonales , Células Presentadoras de Antígenos/fisiología , Antígenos CD2 , Complejo CD3 , División Celular/inmunología , Células Clonales , HumanosRESUMEN
Four antifungal agents have been screened in vitro for their immunosuppressive effects on proliferative responses in human mixed lymphocyte cultures (MLC). A hierarchy of inhibitory activity was observed, where itraconazole was greater than ketoconazole greater than miconazole greater than fluconazole, with itraconazole as suppressive as cyclosporin A, and fluconazole completely without suppressive activity. The mechanism of inhibition did not involve blockade of T-cell growth factor production and, consistent with this, interleukin-2-dependent T-cell clone proliferation was blocked by these agents in the same order of decreasing activity as in MLC. The secretion of cytokines without known T-cell growth factor activity (interferon-gamma, tumour necrosis factor-alpha) was also not significantly blocked by these agents. These results therefore demonstrate that antifungal azole drugs may be variably strongly immunosuppressive for human T-lymphocyte proliferation in vitro, but none appear to be so via a mechanism involving inhibition of cytokine secretion.
Asunto(s)
Antifúngicos/farmacología , Inmunosupresores , Linfocitos T/efectos de los fármacos , Citocinas/metabolismo , Fluconazol/farmacología , Humanos , Técnicas In Vitro , Interleucina-2/farmacología , Itraconazol , Cetoconazol/análogos & derivados , Cetoconazol/farmacología , Activación de Linfocitos/efectos de los fármacos , Miconazol/farmacología , Linfocitos T/inmunologíaRESUMEN
Although interleukin (IL)-10 inhibited lymphocyte proliferation in mixed lymphocyte cultures (MLC) and blocked stimulation of alloreactive T cell clones (TCC) by peripheral blood mononuclear cells (PBMC), the cells surviving culture with IL-10 showed enhanced viability. A minority of IL-2-dependent T cell lines, moreover, incorporated tritiated thymidine when cultured with IL-10 alone; their proliferation with IL-10 was dose-dependent, prevented by addition of neutralizing antisera to IL-10 but not to IL-2 and/or IL-4 and observed both shortly (4 days) and later (7-10 days) after T cell allostimulation. Examination of the proliferative responses to IL-10 of a panel of TCC revealed heterogeneity of responsiveness: whereas only one of five CD8+ TCR2 (T cell receptor alpha, beta)-TCC proliferated with IL-10, three of five CD4+ TCR2-TCC proliferated, one of them strongly. In contrast, all three TCR1(gamma delta)-TCC tested responded to IL-10, albeit rather weakly. These results therefore suggest that in addition to its well-established inhibitory action on T cell activation, IL-10 may also exert positive influences on clonal expansion of subsets of preactivated T cells.
Asunto(s)
Interleucina-10/farmacología , Subgrupos de Linfocitos T/efectos de los fármacos , Linfocitos T CD4-Positivos/efectos de los fármacos , Células Cultivadas , Replicación del ADN/efectos de los fármacos , Humanos , Inmunofenotipificación , Interferón gamma/biosíntesis , Interleucina-10/metabolismo , Interleucina-2/biosíntesis , Interleucina-2/farmacología , Interleucina-4/biosíntesis , Interleucina-4/farmacología , Interleucina-7/farmacología , Activación de Linfocitos/efectos de los fármacos , Prueba de Cultivo Mixto de LinfocitosRESUMEN
In a study aimed at correlating cytokine levels in synovial fluid with the pathology of rheumatoid arthritis (RA), tumour necrosis factor alpha, interleukin 1 beta and interferon gamma were immunoassayed in 27 patients with RA, 16 patients with other arthritides, 23 with osteoarthritis, 13 patients with trauma, and 18 patients at necropsy without inflammatory disease and not known to have had joint disease (median 27 hours after death). The results for interleukin 1 beta clearly show higher cytokine levels in patients with RA and other arthritides than in patients with osteoarthritis, trauma, or the patients at necropsy. Interferon gamma levels in patients with osteoarthritis and the patients at necropsy, however, were significantly greater than in patients with RA, and tumour necrosis factor alpha levels were also greater in the patients at necropsy compared with patients with RA. This study also correlated histomorphological patterns of synovitis and indicators of local inflammatory activity with synovial fluid cytokine levels, showing, for example, a positive association of interleukin 1 beta titre and a negative association of interferon gamma titre with ulcerogranulomatous synovitis (itself associated with RA). Taken together, these results extend and strengthen data suggesting a possible part played by increased synovial fluid levels of interleukin 1 beta in joint destruction in RA, but provide no evidence for increases in levels of tumour necrosis factor alpha or interferon gamma affecting the disease pathology.
Asunto(s)
Artritis Reumatoide/metabolismo , Citocinas/análisis , Líquido Sinovial/química , Adulto , Anciano , Artritis/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Interferón gamma/análisis , Interleucina-1/análisis , Masculino , Persona de Mediana Edad , Osteoartritis/metabolismo , Factor de Necrosis Tumoral alfa/análisisRESUMEN
In order to study extrathymic differentiation in vitro, CD7+CD3- lymphocytes were sorted from normal human bone marrow and cultured under conditions of limiting dilution together with irradiated pooled allogeneic peripheral blood mononuclear cells (PBMC) and phytohemagglutinin (PHA) in the presence of 1000 U/ml of interleukin-2 (IL-2). One clone was obtained that failed to react with monoclonal antibody (mAb) TCR delta 1 (TCR1, gamma/delta-specific) or WT31 (TCR2, alpha/beta-specific). From day 35 through day 74 in culture, the surface phenotype of this clone evolved into CD3+, CD4+, CD8-, TCR2+, TCR1-, and was further characterized as CD2+, CD45RO+, CD16-, and CD56-. The presence of mRNA for TCR alpha and beta but not gamma and delta chains was confirmed by Northern blotting. Accessory cell-dependent autocrine proliferative responses to PHA (most likely driven by IL-2) were initially absent, but became measurable at the same time as the TCR was acquired. However, in the absence of PHA, the clone failed to respond to a panel of homozygous B-cell lines representing the majority of MHC class II alleles. Autoreactivity was also not demonstrable. Cytotoxicity was limited to MHC unrestricted "natural killer (NK)-like" lysis of K562 target cells, with no autocytotoxicity detected. The NK-like lysis diminished over time in parallel with the acquisition of surface TCR. The cloned cells were not suppressive for mature lymphocyte proliferation. After stimulation, the cells secreted tumor necrosis factor alpha and granulocyte/macrophage colony-stimulating factor (GM-CSF) detected by immunoassays, and T-cell growth factors, most likely IL-2, as detected by bioassays. Polymerase chain-reaction methods demonstrated the presence of mRNA for IL-2, IL-3, IL-4, IL-9, interferon-gamma, and GM-CSF in these cells after stimulation with PHA and B-LCL. These results suggest that cells with the phenotype and some functional characteristics of mature T lymphocytes can evolve extrathymically in vitro from T-cell precursors sorted from normal human bone marrow.
Asunto(s)
Células de la Médula Ósea , Complejo CD3/biosíntesis , Antígenos CD4/biosíntesis , Receptores de Antígenos de Linfocitos T alfa-beta/biosíntesis , Antígenos CD/análisis , Antígenos CD7 , Antígenos de Diferenciación de Linfocitos T/análisis , Secuencia de Bases , Northern Blotting , Southern Blotting , Células Cultivadas , Citocinas/metabolismo , Pruebas Inmunológicas de Citotoxicidad , Citometría de Flujo , Humanos , Activación de Linfocitos , Datos de Secuencia Molecular , ARN Mensajero/biosíntesis , Linfocitos T/fisiologíaRESUMEN
A condition of hyporesponsiveness can be induced in certain mature human alpha beta (TCR2) cells relatively easily by their stimulation in the absence of costimulatory signals (signal 1 alone). This state of "anergy" has been implicated in tolerance to self and transplanted organs as well as tumors and may represent an important regulatory component of immune responsiveness. Little is known about whether the same condition applies to gamma delta (TCR1) cells. We therefore undertook to investigate anergy induction in TCR1 cell clones using several approaches known to induce this state in TCR2 cells. First, TCR1 clones were found not to be anergized by culture on immobilized CD3 monoclonal antibody (mAb), while the majority of TCR2 clones were anergized. Second, blocking of autocrine proliferation (stimulated in TCR1 or TCR2 clones by mitogen in the presence of accessory cells) using CTLA-4-lg, a soluble B7 family counterreceptor resulted in anergy induction in TCR2 cells but not TCR1 cells, although experiments with CHO cells transfected with B7-1 (CD80) genes confirmed that these TCR1 clones were responsive to costimulation with B7. Third, blocking mitogen-induced proliferation with anti-IL 2 receptor antibodies and anti-IL 2 antisera resulted in anergy induction in TCR2 but not TCR1 cells. Fourth, stimulation with the calcium ionophore ionomycin also anergized TCR2 but not TCR1 cells. In all four systems, but especially in the latter, stimulation by signal 1 alone resulted in high levels of cell death (> 50%) which was similar for both TCR1 and TCR2 cells. Therefore, these data may reflect a high level of resistance to tolerance induction (manifested as proliferative anergy) but not to clonal deletion (manifested as stimulation-dependent cell death) on the part of TCR1 cells.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Muerte Celular/inmunología , Anergia Clonal/inmunología , Inmunoconjugados , Receptores de Antígenos de Linfocitos T gamma-delta/inmunología , Abatacept , Animales , Anticuerpos Monoclonales/inmunología , Antígenos CD , Antígenos de Diferenciación/inmunología , Complejo CD3/inmunología , Células CHO , Antígeno CTLA-4 , Células Clonales , Cricetinae , Cricetulus , Humanos , Inmunofenotipificación/métodos , Interleucina-2/inmunología , Ionomicina/farmacología , Mitógenos/farmacología , Receptores de Antígenos de Linfocitos T alfa-beta/inmunología , Receptores de Interleucina-2/inmunologíaRESUMEN
To enrich low-density human bone marrow (BM) cells for putative progenitors of T-lymphocytes, CD7+ CD3- cells were sorted (purity was estimated at > 99.9%) and cultured under limiting dilution conditions with irradiated allogeneic stimulator cells, interleukin (IL) 2, and PHA. Clonal populations were available for analysis from Day 25 onward. By this time, all clones (n = 54) expressed CD3 and alpha/beta-T cell receptor (TCR2). Fifty percent of the clones were CD4+ and 50% were CD8+, with no double positives, whereas almost all clones obtained under identical conditions from peripheral blood (PB) cells were CD4+. All clones were capable of autocrine proliferation, which was blocked by CD25 or CD71 mAb. Most or all clones tested (n = 15) responded to IL 4 and IL 7 as well as IL 2, but not to IL 3 or GM-CSF and only two responded to IL 9. Most clones accumulated mRNA for GM-CSF, IL 2, IL 3, IL 4, IL 5 and also IL 9, but 6 of 11 were negative for IFN-gamma mRNA, and all were negative for IL 6 mRNA. Sixty-two percent of CD4+ and 85% of CD8+ clones (total 70% of all clones) mediated lectin-dependent cell lysis; but whereas 35% of CD4+ and 65% of CD8+ clones (total 46% of all clones) lysed K562 natural killer (NK)-susceptible targets, only 24% of CD4+ and 5% of CD8+ clones (total 17% of all clones) killed lymphokine-activated killer (LAK)-susceptible Daudi cells. Only three clones lysed allogeneic LCL targets and none lysed autologous targets. Furthermore, none of the clones proliferated when stimulated by autologous cells, neither did they suppress proliferative responses of autologous cells. These results suggest that CD3- cells from the bone marrow can acquire functional cytotoxic and proliferative programs extrathymically during in vitro culture with IL 2, mitogens and allogeneic cells, but do not manifest autoreactivity in the three test systems, cytotoxicity, suppression, or autocrine proliferation.
Asunto(s)
Células de la Médula Ósea , Médula Ósea/inmunología , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/inmunología , Linfocitos T/citología , Linfocitos T/inmunología , Antígenos de Diferenciación de Linfocitos T/genética , Antígenos de Diferenciación de Linfocitos T/metabolismo , Secuencia de Bases , Diferenciación Celular , Separación Celular , Células Clonales/citología , Células Clonales/efectos de los fármacos , Células Clonales/inmunología , Citocinas/genética , Citocinas/metabolismo , Citocinas/farmacología , Citotoxicidad Inmunológica , Cartilla de ADN/genética , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Técnicas In Vitro , Activación de Linfocitos , Mitógenos/farmacología , Datos de Secuencia Molecular , ARN Mensajero/genética , ARN Mensajero/metabolismo , Linfocitos T/efectos de los fármacosRESUMEN
We monitored patients treated for 5 days with continuous infusion of increasing doses (3 to 6 x 10(6) U/d) of natural interleukin-2 (IL-2). CD16+, CD25+, and CD56+ cells increased after treatment. Plasma tumor necrosis factor-alpha (TNF-alpha) levels, but not interferon-gamma (IFN-gamma) levels, increased during IL-2 treatment, but spontaneous and IL-2-stimulated TNF-alpha secretion in vitro remained abnormally low. However, mitogen-stimulated TNF-alpha release was normal. Mitogen-stimulated, but not IL-2-stimulated, IFN-gamma release was strongly depressed. Low spontaneous and IL-2-stimulated cytotoxicity on K562 or Daudi increased after treatment. Low suppressor cell generation also normalized after treatment. This appears to be the first reported study of immunologic monitoring of cancer patients treated with natural rather than recombinant IL-2.